← Library
Hexarelin
Research Use
Also known as Examorelin, EP 23905
Function
Primary
GH secretagogue · Cardioprotection (research)
Secondary
Body composition
Mechanism
Potent ghrelin / GHS-R1a agonist — stimulates pituitary GH release; direct cardioprotective effects via GHS-R1b on cardiomyocytes; reduces cardiac fibrosis.
Evidence
Pre-clinical / Observational
Research
Phase I/II cardiac studies; robust GH-axis data
Dosing
Range
100–200 mcg/dose
Frequency
1–2× daily
Route
Subcutaneous
Cycling
Pulsed: 4 weeks on / 4 weeks off.
Benefits
- ·Strong GH release
- ·Cardioprotective signaling in models
- ·Body composition support
Risks
- ·Rapid desensitization with chronic use
- ·Elevated cortisol and prolactin
- ·Hunger stimulation
Contraindications
- ·Active malignancy
- ·Pregnancy
Regulatory
Not FDA-approved; research use
Functional Groups
Cited Works
- Imbimbo BP et al. Hexarelin: a novel GH-releasing peptide. J Endocrinol Invest. 1994;17:325.